Monoclonal antibodies for treatment of cold agglutinin disease

References

• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229–1253.
   PubMed Web of Science ®Google Scholar
• Randen U, Troen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99:497–504.
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–1748.
   PubMed Web of Science ®Google Scholar
• Malecka A, Delabie J, Ostlie I, et al. Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv. 2020;4:993–996.
   PubMed Web of Science ®Google Scholar
• Malecka A, Troen G, Tierens A, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol. 2018;183:838–842.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124:2930–2936.
   PubMed Web of Science ®Google Scholar
• Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed). 1981;282:2023–2027.
   PubMed Web of Science ®Google Scholar
• Jager U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020;41:100648. DOI:10.1016/j.blre.2019.100648
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385:1407–1419.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W, D’Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480–488. DOI:10.1182/blood.2020005674
   PubMed Web of Science ®Google Scholar
• Hansen DL, Berentsen S, Fattizzo B, et al. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol. 2021;96:E262–265.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91:460–466.
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122:1114–1121. DOI:10.1182/blood-2013-02-474437
   PubMed Web of Science ®Google Scholar
• Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56:409–416.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Roth A, Randen U, et al. Cold agglutinin disease: current challenges and future prospects. J Blood Med. 2019;10:93–103.
   PubMed Web of Science ®Google Scholar
• Marsh WL. Anti-i: a cold antibody defining the ii relationship in human red cells. Br J Haematol. 1961;7:200–209.
   PubMed Web of Science ®Google Scholar
• Malecka A, Troen G, Tierens A, et al. Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica. 2016;101:e361–4.
   PubMed Web of Science ®Google Scholar
• Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590.
   PubMed Web of Science ®Google Scholar
• Landsteiner K. Über Beziehungen zwischen dem Blutserum und den Körperzellen. Münch Med Wschr. 1903;50:1812–1814.
   Google Scholar
• Schubothe H. The cold hemagglutinin disease. Semin Hematol. 1966;3:27–47.
   PubMedGoogle Scholar
• Roth A, Bommer M, Huttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2:2543–2549.
   PubMed Web of Science ®Google Scholar
• Shiiya C, Ota M. Cold agglutinin disease presenting as livedo racemosa. CMAJ. 2017;189:E781.
   PubMed Web of Science ®Google Scholar
• Poldre P, Pruzanski W, Chiu HM, et al. Fulminant gangrene in transient cold agglutinemia associated with Escherichia coli infection. Can Med Assoc J. 1985;132:261–263.
   PubMed Web of Science ®Google Scholar
• Bylsma LC, Gulbech Ording A, Rosenthal A, et al. Thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3:2980–2985.
   PubMed Web of Science ®Google Scholar
• Hansen DL, Moller S, Berentsen S, et al. Mortality in cold agglutinin disease shows seasonal pattern. Transfusion. 2022;62:1460–1461.
   PubMed Web of Science ®Google Scholar
• Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4:628–635.
   PubMed Web of Science ®Google Scholar
• Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55:141–149.
   PubMed Web of Science ®Google Scholar
• Berentsen S. Role of complement in autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42:303–310.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126:2459–2465.
   PubMed Web of Science ®Google Scholar
• Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 2001;54:239–242.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Hill A, Hill QA, et al. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol. 2019;10:2040620719873321.
   Web of Science ®Google Scholar
• Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood. 1987;69:820–826.
   PubMed Web of Science ®Google Scholar
• Jain MD, Cabrerizo-Sanchez R, Karkouti K, et al. Seek and you shall find–but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery. Transfus Med Rev. 2013;27:65–73.
   PubMed Web of Science ®Google Scholar
• Litman GW. Sharks and the origins of vertebrate immunity. Sci Am. 1996;275:67–71.
   PubMedGoogle Scholar
• Bendix BJ, Tauscher CD, Bryant SC, et al. Defining a reference range for cold agglutinin titers. Transfusion. 2014;54:1294–1297.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170:134–138.
   PubMed Web of Science ®Google Scholar
• Paulus A, Akhtar S, Yousaf H, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7(5):e565.
   PubMedGoogle Scholar
• Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021;138:2002–2005.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Michel M, Zaninoni A, et al. Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. Haematologica. 2021;106:622–625.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–2466.
   PubMed Web of Science ®Google Scholar
• Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. Sci Rep. 2018;8:124.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Pettine L, et al. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. Blood. 2019;133:996–998.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol. 2001;115:79–83.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103:2925–2928.
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253–260.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91:546–551.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vagan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116:3180–3184. DOI:10.1182/blood-2010-06-288647
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a nordic prospective multicenter trial. Blood. 2017;130:537–541. DOI:10.1182/blood-2017-04-778175
   PubMed Web of Science ®Google Scholar
• Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol. 1996;53:279–280.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57–66.
   PubMed Web of Science ®Google Scholar
• Gueli A, Gottardi D, Hu H, et al. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Blood Transfus. 2013;11:311–314.
   PubMed Web of Science ®Google Scholar
• Jager U, D’Sa S, Schorgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019;133:893–901.
   PubMed Web of Science ®Google Scholar
• Roth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022;140:980–991. DOI:10.1182/blood.2021014955
   PubMedGoogle Scholar
• Aggarwal R, Sestak AL, D’Souza A, et al. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus. 2010;19:52–57.
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Schoergenhofer C, Derhaschnig U, et al. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv. 2020;4:997–1005.
   PubMed Web of Science ®Google Scholar
• Roth A, Barcellini W, D’Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384:1323–1334. DOI:10.1056/NEJMoa2027760
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Jaeger U, Fillitz M, et al. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: a phase I, open-label, extension trial. Br J Haematol. 2022;198:e59–62.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Sutimlimab: first approval. Drugs. 2022;82:817–823.
   PubMedGoogle Scholar
• Bartko J, Schoergenhofer C, Schwameis M, et al. A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway. Clin Pharmacol Ther. 2018;104:655–663.
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Gilbert J, Jager U, et al. Combined integrated protocol/basket trial design for a first-in-human trial. Orphanet J Rare Dis. 2016;11:134.
   PubMed Web of Science ®Google Scholar
• Nikitin PA, Rose EL, Byun TS, et al. C1s inhibition by BIVV009 (Sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro. J Immunol. 2019;202:1200–1209.
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Jaeger U, Fillitz M, et al. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood Adv. 2022. DOI:10.1182/bloodadvances.2022008574
   PubMedGoogle Scholar
• Gertz MA. Updates on the diagnosis and management of cold autoimmune hemolytic anemia. Hematol Oncol Clin North Am. 2022;36:341–352.
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I treat cold agglutinin disease. Blood. 2021;137:1295–1303.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W, D’Sa S, et al. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy. 2022;14:1191–1204.
   PubMed Web of Science ®Google Scholar
• Tvedt THA, Steien E, Ovrebo B, et al. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol. 2022;97:E51–54.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfjord GE. Current treatment options in cold agglutinin disease: b-Cell directed or complement directed therapy? Transfus Med Rev. 2022;36:181–187. DOI:10.1016/j.tmrv.2022.05.001
   PubMed Web of Science ®Google Scholar
• Lansita JA, Mease KM, Qiu H, et al. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36:449–462.
   PubMed Web of Science ®Google Scholar
• Gertz MM MA, Qiu H, PhD LK, et al. ANX005, an inhibitory antibody against c1q, blocks complement activation triggered by cold agglutinins in human disease. Blood. 2016;128(22):1265.
   Web of Science ®Google Scholar
• Chow T, Shamszad P, Vinnard C, et al. First-in-human study with SAR445088-A novel selective classical complement pathway inhibitor. Clin Transl Sci. 2023;16(4):673–685.
   PubMed Web of Science ®Google Scholar
• Van de Walle I, Silence K, Budding K, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021;147:1420–1429 e7.
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, de Latour RP, Risitano AM. Advancing therapeutic complement inhibition in hematologic diseases: pNH and beyond. Blood. 2022;139:3571–3582.
   PubMedGoogle Scholar
• Hillmen P, Szer J, Weitz I, et al. Risitano a and peffault de la tour R. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028–1037.
   PubMed Web of Science ®Google Scholar
• Federico Grossi M, Merrill Kingman Shum MD, Morie A, et al. Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with Autoimmune Hemolytic Anemia (AIHA). Blood. 2018;132(Supplement 1):3623.
   Google Scholar
• Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132:547–550.
   PubMed Web of Science ®Google Scholar
• Yao M, Zhang J, Li Y, et al. Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia. Medicine (Baltimore). 2022;101:e28679.
   PubMed Web of Science ®Google Scholar
• Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2:2550–2553.
   PubMed Web of Science ®Google Scholar
• Tomkins O, Berentsen S, Arulogun S, et al. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020;95(10). DOI:10.1002/ajh.25932
   Web of Science ®Google Scholar